Please login to the form below

Not currently logged in
Email:
Password:

John Cooper takes over as CEO of Discovery Labs

Replaces W Thomas Amick who resigns

Specialty biotech company Discovery Labs has appointed John Cooper as its new CEO following the resignation of former chair and CEO W Thomas Amick.

Cooper will also continue to serve in his positions as president and chief financial officer while board member John Leone will take over as chair.

Amick's resignation comes after nine years serving at the Pennsylvania-based firm as a board member, six years as chair and just over two years as CEO.

During his time in charge, Discovery Labs released its first product Surfaxin (lucinactant) onto the market for use in the prevention of a respiratory distress syndrome (RDS).

Cooper will now have responsibility for ensuring the drug's commercial success, as well as steering the development of Aerosruf – an inhaled version of Surfaxin to be used with Discovery's Afectair device to deliver aerosolised medicines.

Prior to joining Discovery in 2001, he served as senior VP and chief financial officer of Chrysalis International Corporation, senior VP and chief financial officer of DNX Corporation and chief financial officer of Taratec Development Corporation.

The new chair Leone joined the Discovery board in November 2012, having previously spent time as president and CEO at Cambrex Corporation and senior VP and chief operating officer of US commercials operations at Aventis.

Joseph Mahady, who spent 30 years at Wyeth – including a period as president – has also been appointed to the Discovery board.

9th January 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics